RebeccaAnnPrevisMD

Obstetrics & Gynecology • Durham, NC

Gynecologic Oncology

Physician

Join to view full profile

Dr. Previs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Previs' full profile

Already have an account?

Office
20 Duke Medicine Cir
Durham, NC 27710
Phone+1 888-275-3853

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2013 - 2017
Duke University HospitalResidency, Obstetrics and Gynecology, 2009 - 2013
University of Virginia School of MedicineClass of 2009
The University of Texas Graduate School of Biological SciencesMS

Certifications & Licensure

NC State Medical License 2009 - 2026
TX State Medical License 2015 - 2019
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

A Study of LY3405105 in Participants With Advanced Cancer Start of enrollment: 2019 Jan 31
Terminated
Phase 1
Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients Start of enrollment: 2019 Aug 08
Completed
Not Applicable

Publications & Presentations

PubMed

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Amma Asare, Rebecca Ann Previs, Daniel Spinosa, Bryan Fellman, Amelia L Scott
Gynecologic Oncology. 2025-02-22
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Aine Clements, Danielle Enserro, Kyle C Strickland, Rebecca Previs, Daniela Matei
Gynecologic Oncology. 2025-02-01
From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates.
Heidi C Ko, Kyle C Strickland, Dana Jaggessarsingh, Alicia Dillard, Michelle Green
Frontiers in Oncology. 2025-01-01

Journal Articles

Differential Expression of Immune Related Genes in High-Grade Ovarian Serous Carcinoma
Rebecca A Previs, Angeles Alvarez Secord, Gynecologic Oncology

Lectures

Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Outcomes4Me Inc.: Outcomes4Me and Labcorp Study Reveals Digital Education Can Increase HER2-Low Awareness for Metastatic Breast Cancer PatientsNovember 26th, 2024
What Is HER2? What Does HER2-Low Mean for Treatment Options?October 29th, 2024
Labcorp Perspectives: Optimizing Biomarker Testing in Advanced NSCLC: Insights on Comprehensive Genomic Profiling (CGP)November 20th, 2024